ライフサイエンスコーパス: disability-adjusted life year

1 ard for low-income countries (140 US dollars/disability-adjusted life-year).

2 SB intake (4.5% of diabetes mellitus-related disability-adjusted life years).

3 calculated from estimates of the value of a disability-adjusted life year.

4 emental cost-effectiveness ratio of $363 per disability-adjusted life-year.

5 estimated combined burden of over 87 million disability-adjusted life years.

6 e for an estimated annual loss of 70 million disability-adjusted life years.

7 able risk factor for worldwide mortality and disability-adjusted life years.

8 ,000 (minimum = 580,000 maximum = 1 million) disability-adjusted life years.

9 environmental impacts were also estimated as disability-adjusted life years.

10 ts systems, quality-adjusted life-years, and disability-adjusted life-years.

11 e generated and applied to 2019 estimates of disability-adjusted life-years.

12 l deaths, as well as approximately 3% of all disability-adjusted life-years.

13 reporting measures of incidence, burden, and disability-adjusted life-years.

14 global burden of IHD increased by 29 million disability-adjusted life-years (29% increase) between 19

15 314), primarily through suicide, and 184 636 disability-adjusted life-years (95% CI, 109 321-252 887)

16 In Australia, the number of disability-adjusted life years among Aboriginal and Torr

17 le worldwide, with an estimated 0.88 million disability-adjusted life years and 34,000 deaths in 2019

18 sed the number of averted cases, deaths, and disability-adjusted life years and the cost-effectivenes

19 We identified standards of utilisation per disability-adjusted life-year and estimated additional s

20 lth burden and on the cost-effectiveness per disability-adjusted life-year and lives saved were calcu

21 aharan Africa will probably lose 2.3 million disability-adjusted life-years and US$3.5 billion of eco

22 s of life lost, years lived with disability, disability-adjusted life-years, and risk factors to anal

23 Thirty-seven percent of disability-adjusted-life-years arise from human infectio

24 rk to calculate the proportion of deaths and disability adjusted life years attributable to PM2.5 exp

25 In 2019, the proportion of age-standardized disability-adjusted life-years attributable to smoking w

26 patient outcomes data, and measured cost per disability adjusted life year averted and cost per life

27 cated pediatric OR has an ICER of $37.25 per disability adjusted life year averted or $3321 per life

28 ll scenarios, the highest estimated cost per disability-adjusted life year averted (uniform strategy

29 estimates ranging from US$2.97 to $52.92 per disability-adjusted life year averted in the 15 countrie

30 ut 2,000 and 5,000 international dollars per disability-adjusted life year averted, and was consisten

31 and $4080 for Sri Lanka, per cardiovascular disability-adjusted life year averted, which showed COBR

32 iveness ratio (ICER) of $1.50 ($US 2010) per disability-adjusted life year averted.

33 , a cost-effectiveness threshold of $500 per disability-adjusted life years averted, and a discount r

34 ease model in order to explore the impact on disability-adjusted life years averted, program cost, an

35 [50%], and high [75%]) in terms of cost per disability-adjusted life-year averted (DALY).

36 fectiveness ratio (United States dollars per disability-adjusted life-year averted and dollars per li

37 cination was very cost effective (with every disability-adjusted life-year averted costing less than

38 The cost per disability-adjusted life-year averted for alternative "w

39 The discounted cost per disability-adjusted life-year averted for restricted, fl

40 The discounted dollars per disability-adjusted life-year averted has a very high pr

41 ocietal perspective (saving US$4.0-300.0 per disability-adjusted life-year averted in the countries s

42 16, 2012, to estimate the costs and cost per disability-adjusted life-year averted of introducing Xpe

43 cost-effectiveness of US$959 (633-1,485) per disability-adjusted life-year averted over 10 y.

44 $3000 in Colombia, and $1000 in Ukraine) per disability-adjusted life-year averted were considered co

45 cost-effectiveness ratio (discounted US$ per disability-adjusted life-year averted).

46 a cost-effectiveness threshold of US$500 per disability-adjusted life-year averted, $34 million per y

47 income countries was $88, $291, and $329 per disability-adjusted life-year averted, respectively, and

48 ntal cost-effectiveness ratio of US$13.0 per disability-adjusted life-year averted, which can be cons

49 BTT was more cost-effective at $205 to $272/disability-adjusted life-year averted, which was $142 to

50 ew infection averted, and $351 (290-424) per disability-adjusted life-year averted.

51 would be associated with a cost of $5.07 per disability-adjusted life-year averted.

52 sociated with a base case cost of $74.73 per disability-adjusted life-year averted.

53 tiveness ratios ranged from $1.1 to $543 per disability-adjusted life-year averted.

54 the disease costs averted, with the cost per disability-adjusted life-years averted being less than $

55 savings and health benefits (infections and disability-adjusted life-years averted) according to all

56 We estimated health effects (ie, disability-adjusted life-years averted) and resource imp

57 % of setting scenarios and cost-saving (with disability-adjusted life-years averted) in 58% of scenar

58 ese properties would result in >0.53 million disability-adjusted-life-years averted over 2022-2042, w

59 ompared with UC was $3428.71 to $6857.68 per disability-adjusted life year avoided, and $0.80 to $1.6

60 osis, and 1000 cases of HCC, and 8.9 million disability-adjusted life years between 2020 and 2040.

61 About 32.4% of the growth in global IHD disability-adjusted life-years between 1990 and 2010 was

62 the burden of disease (defined by death and disability-adjusted life years) by comparing two WHO reg

63 Disability-adjusted life years, combining years of life

64 ness was assessed using incremental cost per disability adjusted life year (DALY) averted compared ag

65 timate of US$94 (95% CrI: US$51, US$166) per Disability Adjusted Life Year (DALY) averted, PMI-funded

66 nalysis to calculate ranges for the cost per disability-adjusted life year (DALY) averted for each in

67 discounted costs per incremental discounted disability-adjusted life year (DALY) averted, compared w

68 y form a significant component of the dengue disability-adjusted life year (DALY) burden estimates.

69 eliable and valid prevalence, incidence, and disability-adjusted life year (DALY) estimates of oral c

70 ic for setting public health priorities, the disability-adjusted life year (DALY), is unsuited to par

71 cal assessment and uses a standard unit, the disability-adjusted life year (DALY), to aid comparisons

72 We developed a disability-adjusted life year (DALY)-based estimate of t

73 (YLL), 4) years lost to disability (YLD), 5) disability-adjusted life years (DALY's), 6) direct costs

74 Disability-adjusted life years (DALY) are a common publi

75 Background Disability-adjusted life years (DALY) are a common publi

76 ta on the prevalence, incidence, deaths, and disability-adjusted life years (DALY) of AEMT in the EMR

77 odity categories and range from 0.025 to 6.6 disability-adjusted life years (DALY) per million dollar

78 as burden of disease) on the order of 0.2-9 disability-adjusted life years (DALY) per year of operat

79 effectiveness ratios (ICERs) as the cost per disability-adjusted life-year (DALY) and cost per HIV in

80 d both in terms of the cost of treatment per disability-adjusted life-year (DALY) averted (one DALY i

81 We calculated the costs per disability-adjusted life-year (DALY) averted and associa

82 a cost-effectiveness threshold of US$500 per disability-adjusted life-year (DALY) averted for our mai

83 calculated the incremental cost (in US$) per disability-adjusted life-year (DALY) averted to compare

84 comparing the incremental cost of Avahan per disability-adjusted life-year (DALY) averted versus a no

85 cost-effectiveness threshold of US $500 per disability-adjusted life-year (DALY) averted, a 3% annua

86 , a cost-effectiveness threshold of $500 per disability-adjusted life-year (DALY) averted, an annual

87 assuming a WTP value of at least US$200 per disability-adjusted life-year (DALY) averted, or assumin

88 (ICER) was calculated in 2014 US dollars per disability-adjusted life-year (DALY) averted.

89 d to a cost-effectiveness threshold of $2480/disability-adjusted life-year (DALY) averted.

90 ic cost-effectiveness threshold of US$80 per disability-adjusted life-year (DALY) averted.

91 a cost-effectiveness threshold of US$500 per disability-adjusted life-year (DALY) averted.

92 per capita gross domestic product (GDP) per disability-adjusted life-year (DALY) averted.

93 Outcome measures were cost per disability-adjusted life-year (DALY) averted; cost per l

94 Disability-adjusted life-year (DALY) changes between 199

95 Published disability-adjusted life-year (DALY) estimates suggest t

96 st per HIV-1 infection averted, and cost per disability-adjusted life-year (DALY) saved.

97 ection averted, and the incremental cost per disability-adjusted life-year (DALY) saved.

98 Incremental costs per disability-adjusted life-year (DALY) were estimated and

99 averted, cost per case averted, and cost per disability-adjusted life-year (DALY).

100 f primary prevention alone saved 3.6 million disability-adjusted life-years (DALY) per annum at an in

101 n, CSI), risk target used (infection risk vs disability adjusted life years [DALY] on a per-exposure

102 ldhood and maternal underweight (138 million disability adjusted life years [DALY], 9.5%), unsafe sex

103 The median CER of circumcision ($13.78 per disability-adjusted life year [DALY]) was similar to tha

104 cost $314-$1664 per case averted ($790-$4221/disability-adjusted life-year [DALY] averted) in Hondura

105 uct [GDP] per capita, and GDP per capita per disability-adjusted life-year [DALY]).

106 ntal cost-effectiveness ratios (ICERs; $ per disability-adjusted life-year [DALY]).

107 al and microbial hazards were assessed using disability adjusted life years (DALYs) as the common met

108 Data on the prevalence, deaths, and disability adjusted life years (DALYs) of COPD, and its

109 nt modelling was used to estimate changes in Disability Adjusted Life Years (DALYs) resulting from ch

110 Main causes of disability adjusted life years (DALYs) were ischaemic he

111 Globally, in terms of disability adjusted life years (DALYs), as the loss due

112 number of infections, sequelae, deaths, and Disability Adjusted Life Years (DALYs), by age and regio

113 f foodborne illnesses, sequelae, deaths, and Disability Adjusted Life Years (DALYs), for all diseases

114 timate the global burden of FBDs in terms of Disability Adjusted Life Years (DALYs).

115 sed by the 31 hazards in 2010 was 33 million Disability Adjusted Life Years (DALYs); children under f

116 We calculated disability adjusted life-years (DALYs) for each policy,

117 ne, the program averted 33.3 deaths or 244.5 disability adjusted life-years (DALYs) per 100 person-ye

118 se combinations could result in carcinogenic disability-adjusted life years (DALYs) above the accepta

119 burden of CT and cCMV in Belgium in terms of disability-adjusted life years (DALYs) and identify data

120 Historical data on disability-adjusted life years (DALYs) and mortality fro

121 We assessed the burden of dengue illness as disability-adjusted life years (DALYs) and patient costs

122 The global trends for disability-adjusted life years (DALYs) and years of life

123 Outcomes to measure effectiveness were disability-adjusted life years (DALYs) and years of life

124 Disability-adjusted life years (DALYs) are used to evalu

125 s and fine particulate matter (PM2.5), using disability-adjusted life years (DALYs) as a common metri

126 tatus report on the incidence, mortality and disability-adjusted life years (DALYs) associated with k

127 veloped a model to investigate the number of disability-adjusted life years (DALYs) averted by a hydr

128 sociated unit costs; we quantified impact as disability-adjusted life years (DALYs) averted.

129 s, neonatal deaths, congenital syphilis, and disability-adjusted life years (DALYs) averted.

130 imum impact of different dietary patterns on disability-adjusted life years (DALYs) by using individu

131 nd (2016); disability weights for estimating disability-adjusted life years (DALYs) from the Global B

132 n schizophrenia's prevalence, incidence, and disability-adjusted life years (DALYs) globally.

133 of incidence, cause-specific mortality, and disability-adjusted life years (DALYs) in China estimate

134 he combined CVD and congenital heart anomaly disability-adjusted life years (DALYs) in the poorest co

135 from passive vaping was derived by computing disability-adjusted life years (DALYs) lost due to expos

136 alysis to assess the reduction in deaths and disability-adjusted life years (DALYs) lost if eight pro

137 9.6 (95% confidence interval (CI): 0.4-18.7) disability-adjusted life years (DALYs) per 1,000 persons

138 : 71.6-89.6) and 642.8 (95% CI: 596.9-689.3) disability-adjusted life years (DALYs) per 1,000 persons

139 HAZ, and WHZ, to minimize the mean number of disability-adjusted life years (DALYs) per child during

140 60 years) is highest in high-income regions, disability-adjusted life years (DALYs) per head are 40%

141 Leading causes of disability-adjusted life years (DALYs) predicted by the

142 1990 Global Burden of Disease study proposed disability-adjusted life years (DALYs) to measure diseas

143 m impacts are further aggregated to units of disability-adjusted life years (DALYs) using ReCiPe end

144 An estimated 2249 disability-adjusted life years (DALYs) were averted over

145 Incidence, prevalence, and disability-adjusted life years (DALYs) were extracted fo

146 ountries studied, thus averting 8.34 million disability-adjusted life years (DALYs) yearly.

147 althcare and partial societal perspectives), disability-adjusted life years (DALYs), and incremental

148 into incidences of cardiovascular diseases, disability-adjusted life years (DALYs), and life expecta

149 as utilized to collect incidence, mortality, disability-adjusted life years (DALYs), and years lived

150 st 20% were prepared for 1990 for deaths and disability-adjusted life years (DALYs), by a procedure u

151 idual country, we estimated causes of death, disability-adjusted life years (DALYs), DALY-attributabl

152 Based on funding per 2017 disability-adjusted life years (DALYs), HIV/AIDS receive

153 8 million) of global deaths and 14.4% of all disability-adjusted life years (DALYs), led by ambient P

154 r contributed to 12,528,421 age-standardized disability-adjusted life years (DALYs), with an age-stan

155 Disability-adjusted life years (DALYs), years lived with

156 mortality, and disease burden as measured by disability-adjusted life years (DALYs).

157 ect resistance profile, infectious time, and disability-adjusted life years (DALYs).

158 0 years in 2.0 million (793,800-3.9 million) disability-adjusted life years (DALYs).

159 erculosis episodes, tuberculosis deaths, and disability-adjusted life years (DALYs).

160 sease, along with the attributable number of disability-adjusted life years (DALYs).

161 sease, along with the attributable number of disability-adjusted life years (DALYs).

162 We estimated deaths and disability-adjusted life years (DALYs; sum of years live

163 a much larger impact, averting 1.10 million disability-adjusted life-years (DALYs) and 25% of expect

164 o, we simulated predicted outcomes including disability-adjusted life-years (DALYs) and costs up to 5

165 (PAFs) of risk attributable to ACEs and the disability-adjusted life-years (DALYs) and financial cos

166 Disease burden was evaluated using disability-adjusted life-years (DALYs) and prevalence.

167 00 (95% uncertainty interval 7300 to 21 600) disability-adjusted life-years (DALYs) and saved US$23 0

168 We used disability-adjusted life-years (DALYs) and years lived w

169 Disability-adjusted life-years (DALYs) are a sum of the

170 We calculated disability-adjusted life-years (DALYs) arising from stil

171 used the model to estimate overall cost and disability-adjusted life-years (DALYs) associated with a

172 ttributable fraction (PAF) of stroke-related disability-adjusted life-years (DALYs) associated with p

173 every cycle, participants accrued costs and disability-adjusted life-years (DALYs) associated with t

174 health challenge worldwide, with deaths and disability-adjusted life-years (DALYs) attributable to i

175 health-care costs, productivity losses, and disability-adjusted life-years (DALYs) attributable to p

176 sure targets (at 6 months from baseline) and disability-adjusted life-years (DALYs) averted (at 10 ye

177 ment algorithms would affect insulin use and disability-adjusted life-years (DALYs) averted by insuli

178 n-investment analysis, the monetary value of disability-adjusted life-years (DALYs) averted in additi

179 n terms of cervical cancer cases, deaths, or disability-adjusted life-years (DALYs) averted per 1000

180 The primary outcome was total disability-adjusted life-years (DALYs) averted through t

181 Estimates of cases, deaths, and disability-adjusted life-years (DALYs) averted were calc

182 t with the highest incremental cost: 346 000 disability-adjusted life-years (DALYs) averted with an a

183 nalysis, we compared the infections averted, disability-adjusted life-years (DALYs) averted, and uppe

184 n to tuberculosis, mortality, and discounted disability-adjusted life-years (DALYs) averted.

185 remitted depression at 3 and 12 months, and disability-adjusted life-years (DALYs) averted.

186 ductions converted to cardiovascular disease disability-adjusted life-years (DALYs) averted.

187 ted diseases by 1.42 million (1.38-1.48) and disability-adjusted life-years (DALYs) by 27.0 million (

188 We cross-tabulated the quantiles of disability-adjusted life-years (DALYs) by quintiles of D

189 of global numbers of illnesses, deaths, and disability-adjusted life-years (DALYs) due to listeriosi

190 Disability-adjusted life-years (DALYs) for fetal loss or

191 ed annual and lifetime health-care costs and disability-adjusted life-years (DALYs) for individuals,

192 We calculated disability-adjusted life-years (DALYs) for low birthweig

193 eaths, and summed YLLs and YLDs to calculate disability-adjusted life-years (DALYs) for these causes

194 spond to thresholds of $1,582 and $4,746 per disability-adjusted life-years (DALYs) for very cost-eff

195 ted the population attributable fraction and disability-adjusted life-years (DALYs) from HCV-associat

196 Estimated per-person disability-adjusted life-years (DALYs) from tuberculosis

197 d 103.1 million (90.8 million 115.1 million) disability-adjusted life-years (DALYs) in 2015, represen

198 2.4 million rotavirus deaths and >82 million disability-adjusted life-years (DALYs) in 64 of the 72 G

199 ), years lived with a disability (YLDs), and disability-adjusted life-years (DALYs) in England, the U

200 Ls), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) in Norway and its

201 eaths (4.7% of all deaths) and 116.0 million disability-adjusted life-years (DALYs) lost (4.6% of all

202 s old would be expected to reduce the median disability-adjusted life-years (DALYs) lost by 32.3%, bu

203 No studies have estimated disability-adjusted life-years (DALYs) lost due to hip f

204 mortality, mortality-to-incidence ratio, and disability-adjusted life-years (DALYs) lost, by age grou

205 ons to estimate the chronic heath impact, in disability-adjusted life-years (DALYs) lost, due to inha

206 easured the dengue health burden in terms of disability-adjusted life-years (DALYs) lost.

207 9, the incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) of stroke cases i

208 ir age-related burden, defined as the sum of disability-adjusted life-years (DALYs) of these diseases

209 evaluated from a societal perspective using disability-adjusted life-years (DALYs) over a 20-year ho

210 isease) with overall health gains of 420-826 disability-adjusted life-years (DALYs) per 100 000 popul

211 ssessed the global incidence, mortality, and disability-adjusted life-years (DALYs) related to chroni

212 urement of the global burden of disease with disability-adjusted life-years (DALYs) requires disabili

213 We used disability-adjusted life-years (DALYs) to measure the ne

214 The leading cause of disability-adjusted life-years (DALYs) was ischaemic hea

215 Disability-adjusted life-years (DALYs) were calculated a

216 Disability-adjusted life-years (DALYs) were calculated a

217 Disability-adjusted life-years (DALYs) were estimated as

218 ths, 3.9% of years of life lost, and 3.8% of disability-adjusted life-years (DALYs) worldwide.

219 behavioural changes, we estimated 850 fewer disability-adjusted life-years (DALYs), and a saving of

220 Deaths, disability-adjusted life-years (DALYs), and cases averte

221 (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life

222 (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life

223 s were costs, measles cases, measles deaths, disability-adjusted life-years (DALYs), and ICERs measur

224 atric research was correlated with pediatric disability-adjusted life-years (DALYs), deaths, years li

225 Data on the point prevalence, death, and disability-adjusted life-years (DALYs), due to stroke, w

226 e global burden of melioidosis, expressed in disability-adjusted life-years (DALYs), for 2015.

227 life lost, years lived with disability, and disability-adjusted life-years (DALYs), for cancer overa

228 as summarised with age-standardised rates of disability-adjusted life-years (DALYs), for geographical

229 rs lived with disability (YLDs) and 13.0% of disability-adjusted life-years (DALYs), instead of the e

230 (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), life expectancy,

231 y), avoid the loss of 3.73 and 2.19 million disability-adjusted life-years (DALYs), respectively, an

232 (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), summary exposure

233 with household air pollution, as measured by disability-adjusted life-years (DALYs), were estimated f

234 including deaths, incidence, prevalence, and disability-adjusted life-years (DALYs), were produced us

235 ife lived with disability (YLD), deaths, and disability-adjusted life-years (DALYs), with 95% uncerta

236 ation model to estimate net country-specific disability-adjusted life-years (DALYs), years lived with

237 racted data for deaths, prevalence of cases, disability-adjusted life-years (DALYs), years lived with

238 en of NCDs in sub-Saharan Africa in terms of disability-adjusted life-years (DALYs)-with crude counts

239 Change in healthy life-years measured as disability-adjusted life-years (DALYs).

240 tality from scabies, YLDs were equivalent to disability-adjusted life-years (DALYs).

241 , the intervention was estimated to avert 19 disability-adjusted life-years (DALYs; 95% CI 16-21) and

242 patient admissions, 4300 deaths, and 136 000 disability-adjusted-life-years (DALYs).

243 of stroke mortality and burden (measured in disability-adjusted life years [DALYs]) were calculated

244 ndicators included those of health outcomes (disability-adjusted life-years [DALYs] due to communicab

245 health benefits per million population (7332 disability-adjusted life-years [DALYs] in London, and 12

246 plus years lost due to disability [YLD] and disability-adjusted life-years [DALYs]) costs for Europe

247 cal trials in the fields of oncology (46% of disability-adjusted life-years [DALYs]; 43% of participa

248 Disability-adjusted life-years decreased in all EU15+ co

249 ined, including quality-adjusted life-years, disability-adjusted life-years, discounting, half-cycle

250 ainty interval, 9.6 million to 11.5 million) disability-adjusted life-years due to rheumatic heart di

251 ths, 3.9% of years of life lost, and 3.8% of disability-adjusted life years globally.

252 esult in the annual loss of over 200 million disability-adjusted life years globally.

253 ion and is the third most important cause of disability-adjusted life-years globally.

254 he potentially huge, largely undefined DALY (disability-adjusted life years) impact of early childhoo

255 er of IHD deaths since 1990, but >90% of IHD disability-adjusted life-years in 2010 were attributable

256 for 1.14 million (0.73 million-1.98 million) disability-adjusted life-years in 2013.

257 ces but averted approximately 5 million more disability-adjusted life-years in both China and India t

258 19, oral disorders accounted for 8.9 million disability-adjusted life-years in individuals older than

259 MNSS comprised 19% of total disability-adjusted life-years in the Americas in 2015.

260 An estimated 90% of the 87 million disability-adjusted life-years incurred by surgical cond

261 nce, and disability-adjusted life-years (one disability-adjusted life-year is defined as the loss of

262 IHD rates in 74 countries (39%), and stroke disability-adjusted life-year loss rates exceeded IHD ra

263 We analyzed mortality and disability-adjusted life-year loss rates from stroke and

264 % higher to 27.2% lower than IHD, and stroke disability-adjusted life-year loss rates ranged from 6.2

265 cted for a subset of pollutants by computing disability-adjusted life years lost, using available tox

266 4 million people and results in 10.5 million disability-adjusted life-years lost globally.

267 hat together encompass the largest number of disability-adjusted life-years lost in the United States

268 h Asia, accounting for a large proportion of disability-adjusted life-years lost in this region.

269 ually, stroke is associated with the highest disability-adjusted life-years lost of any disease in Ch

270 elfare Loss (WL) was calculated by measuring disability-adjusted-life-years lost to breast cancer alo

271 d using both annual infection (LRT(INF)) and disability-adjusted life year (LRT(DALY)) benchmarks.

272 d at outcomes of EUHC not encompassed by the disability-adjusted life-year metric and related cost-ef

273 In 2019, the death rate, and Disability-adjusted life years of thyroid cancer was 0.4

274 (2.3%) CHD deaths at an incremental cost per disability-adjusted life-year of $25 200.

275 days in 1994 and incidence, prevalence, and disability-adjusted life-years (one disability-adjusted

276 Changes in quality-adjusted life-years, disability-adjusted life-years, or survival and mortalit

277 sed by 32%, with an overall 28% reduction in disability-adjusted life years over the decade.

278 s of $75 million, while averting around 7000 disability-adjusted life-years over 20 years.

279 .3-18.8 AIDS deaths, and could save 2.9-18.6 disability-adjusted life years per 1,000 people.

280 d avert 4,436 infections, 0.34 deaths and 17 disability-adjusted life years per 100,000 doses used.

281 52,589 clinic visits (59%) and would save 58 disability-adjusted life-years per 1000 children annuall

282 stroke incidence, prevalence, mortality, and disability-adjusted life-years rates tend to decline fro

283 Vaccination would prevent the loss of 94,993 disability-adjusted life-years, resulting in an incremen

284 ctful stickers to be between $10 and $45 per disability-adjusted life-year saved.

285 3.7 million hospital visits, and 8.7 million disability-adjusted life-years, saving $188 million in t

286 ear averted, which was $142 to $182 less per disability-adjusted life-year than TTT or hybrid strateg

287 uce child mortality by 10-20%, at a cost per disability-adjusted life-year that is as low as any exis

288 NG, AND PARTICIPANTS: This cohort study used disability-adjusted life-years to measure the 2008 and 2

289 Disability-adjusted life-years to measure the 2008 and 2

290 sociated with funding, whereas the number of disability-adjusted life-years was strongly predictive o

291 Disability adjusted life years were averted with AMETHIS

292 A total of 8.5 (2.8, 19.2) million disability-adjusted life years were related to SSB intak

293 attributable to population growth, and total disability-adjusted life-years were attenuated by a 25.3

294 cycle impacts on human health (expressed in disability adjusted life years) which include other impo

295 m diseases, injuries, and risk factors using disability-adjusted life-years, which need a set of disa

296 eatest single cause of mortality and loss of disability-adjusted life years worldwide, and a substant

297 Severe trauma is the first cause of disability-adjusted life years worldwide, yet most atten

298 isk factor-1.5 million deaths and 33 million disability-adjusted life-years worldwide are attributabl

299 hosis is one of the main causes of death and disability-adjusted life-years worldwide.

300 obal burden of specific cancers, measured by disability-adjusted life-years, years lived with disabil